A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-Head Locations (Trunk and Extremities).

Trial Profile

A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05% in Patients With Actinic Keratoses on Non-Head Locations (Trunk and Extremities).

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Ingenol mebutate (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 10 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. record NCT00917306.
    • 08 Jul 2009 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
    • 23 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top